A transduction strategy has been developed, using fibronectin (FN)assisted retroviral-mediated gene transfer, based on the observation that hematopoietic stem and progenitor cells bind to specific adhesion domains of fibronectin, via the integrins, very late antigen-4 (VLA-4)α4β1 and very late antigen-5 (VLA-5)α5β1. Retrovirus-mediated transduction on a recombinant FN fragment, FN CH-296, containing binding sites for VLA-4 and VLA-5, separated by type III repeats 12 to 14, makes it possible to efficiently target hematopoietic stem and progenitor cells and T-lymphocytes due to colocalization of target cells and retrovirus particles. These gene therapy strategies are applicable to the potential treatment of a variety of acquired and inherited immune disorders.
|Original language||English (US)|
|Number of pages||10|
|Journal||Current Opinion in Molecular Therapeutics|
|State||Published - Nov 18 1999|
- Gene transfer
ASJC Scopus subject areas
- Pharmacology, Toxicology and Pharmaceutics(all)